Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | FOLH1 | Q04609 | 8/20 | 0.42 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.39 |
| ▸ | ALB | P02768 | 2/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15160764 | 0.86 | KMT2A (0.49) | MEN1KMT2AFOLH1NOD1ALB | |
| SCHEMBL15160683 | 0.86 | KMT2A (0.49) | MEN1KMT2AFOLH1NOD1ALB | |
| SCHEMBL763069 | 0.86 | MEN1 (0.53) | MEN1KMT2AFOLH1ALBRECQL | |
| SCHEMBL24796610 | 0.84 | NOD1 (0.58) | NOD1EPHX2 | |
| SCHEMBL14217259 | 0.83 | MEN1 (0.59) | MEN1KMT2AFOLH1NOD1ALB | |
| SCHEMBL16384384 | 0.83 | MEN1 (0.59) | MEN1KMT2AFOLH1NOD1ALB | |
| SCHEMBL13197601 | 0.83 | MEN1 (0.59) | MEN1KMT2AFOLH1NOD1ALB | |
| SCHEMBL16384378 | 0.83 | MEN1 (0.59) | MEN1KMT2AFOLH1NOD1ALB | |
| SCHEMBL20806790 | 0.83 | FOLH1 (0.40) | MEN1KMT2AFOLH1NOD1ALB | |
| SCHEMBL18116882 | 0.82 | MEN1 (0.57) | MEN1KMT2AFOLH1NOD1ALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8653049-B2 | Normuramyl glycopeptide compounds | IMUTHES LIMITED (GB) | 2014-02-18 | — | — | US | disclosed |
| US-20110002983-A1 | COMPOUND | IMUTHES LIMITED (GB) | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110002983-A1 | COMPOUND | C5AR1, C5AR2, ARG1 | MEN1 683/4885KMT2A 713/4885FOLH1 2429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.